<DOC>
	<DOCNO>NCT02955797</DOCNO>
	<brief_summary>The purpose study evaluate quadrivalent meningococcal conjugate vaccine use single-dose toddler vaccine individual either meningococcal vaccine naïve receive one dose monovalent meningococcal C ( MenC ) vaccines infancy . Primary Objectives : - To demonstrate non-inferiority antibody response meningococcal serogroups A , C , Y , W single dose MenACYW conjugate vaccine Nimenrix® toddler either meningococcal vaccine naïve receive monovalent MenC vaccination infancy - To demonstrate non-inferiority antibody response meningococcal serogroups A , C , Y , W single dose MenACYW conjugate vaccine Nimenrix® meningococcal vaccine naïve toddler Secondary Objectives : - To compare antibody response ( geometric mean titer [ GMTs ] ) meningococcal serogroups A , C , Y , W dose MenACYW conjugate vaccine Nimenrix® measure hSBA toddler either meningococcal vaccine naïve receive monovalent MenC vaccination infancy - To compare antibody response ( GMTs ) meningococcal serogroups A , C , Y , W dose MenACYW conjugate vaccine Nimenrix® measure hSBA meningococcal vaccine naïve toddler - To compare antibody response ( GMTs ) meningococcal serogroups A , C , Y , W dose MenACYW conjugate vaccine Nimenrix® measure hSBA toddler receive monovalent MenC vaccination infancy . Observational Objective : - To evaluate safety profile MenACYW conjugate vaccine Nimenrix® .</brief_summary>
	<brief_title>Immunogenicity Safety Investigational Quadrivalent Meningococcal Conjugate Vaccine Toddlers</brief_title>
	<detailed_description>Healthy toddler age 12 23 month enrol randomized depend meningococcal background receive either MenACYW conjugate vaccine Nimenrix® . They assess immunogenicity assessment baseline ( pre-vaccination ) post-vaccination . Safety information collect post-vaccination entire study .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 12 23 month day first study visit Subjects receive recommended standardofcare nonmeningococcal vaccination accord his/her age per local regulation Informed consent form ( ICF ) sign date parent/legally acceptable representative Subject parent/legally acceptable representative able attend schedule visit comply trial procedure Covered health insurance require local regulation Subjects received meningococcal vaccine second year life ( i.e. , 12 month age ) For Inclusion Groups 1 2 : Subjects must receive vaccination meningococcal disease either trial vaccine license meningococcal vaccine ( i.e. , polyvalent , polysaccharide , conjugate meningococcal vaccine contain serogroups A , C , W , Y , B ; monovalent bivalent meningococcal vaccine ) For Inclusion Groups 3 4 : Subjects must previously receive least 1 dose license monovalent meningococcal C conjugate ( MenC ) vaccine infancy ( i.e. , 12 month age ) . Participation 4 week precede trial vaccination plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week ( 28 day ) precede trial vaccination plan receipt vaccine prior Visit 2 except influenza vaccination , may receive least 2 week study investigational vaccine . This exception include monovalent pandemic influenza vaccine multivalent influenza vaccine Receipt immune globulin , blood bloodderived product past 3 month For Groups 1 2 : Vaccination meningococcal disease either trial vaccine license meningococcal vaccine ( i.e. , polyvalent , polysaccharide , conjugate meningococcal vaccine contain serogroups A , C , W , Y , B ; monovalent bivalent meningococcal vaccine ) For Groups 3 4 : Vaccination meningococcal disease either trial vaccine license meningococcal vaccine ( i.e. , polyvalent , polysaccharide , conjugate meningococcal vaccine contain serogroups A , C , W , Y , B ; monovalent B meningococcal vaccine ) , except license monovalent meningococcal C conjugate ( MenC ) vaccination receive infancy Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) History meningococcal infection , confirm either clinically , serologically , microbiologically At high risk meningococcal infection trial ( specifically , limit , subject persistent complement deficiency , anatomic functional asplenia , subject travel country high endemic epidemic disease ) Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine containing substance Personal history Arthuslike reaction vaccination tetanus toxoidcontaining vaccine Personal history GuillainBarré Syndrome Verbal report thrombocytopenia , report parent/legally acceptable representative contraindicate intramuscular vaccination Investigator 's opinion Bleeding disorder receipt anticoagulants 3 week precede inclusion , contraindicate intramuscular vaccination Investigator 's opinion Chronic illness , opinion Investigator , stage might interfere trial conduct completion Moderate severe acute illness/infection ( accord Investigator judgment ) day vaccination febrile illness ( temperature ≥ 38.0°C ) . A prospective subject include study condition resolve febrile event subside Receipt oral injectable antibiotic therapy within 72 hour prior first blood draw Identified natural adopt child Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Meningitis</keyword>
	<keyword>MenACYW conjugate vaccine</keyword>
	<keyword>Nimenrix®</keyword>
	<keyword>Menjugate®</keyword>
</DOC>